INCR News and Press, Intercure Ltd. From 08/28/23

2023-08-28 13:15:00 ET Summary Investing in cannabis stocks has seen a series of mistakes, including underestimating growth deceleration and overestimating synergies from M&A. Alan Brochstein and Julian Lin on why companies in the cannabis industry should be more aggressive in...

2023-08-02 19:22:35 ET Summary In mid-August, InterCure, one of the leaders in the global medical cannabis market, will publish financial results for the 2nd quarter of 2023. According to the Ministry of Health, the consumption of medical cannabis in Israel rose to 4.88 tons in Ju...

2023-07-10 17:23:22 ET InterCure ( NASDAQ: INCR ) has approved the voluntarily delisting of the Company’s common shares from the Toronto Stock Exchange. The Shares are currently listed on the NASDAQ and the Tel Aviv Stock Exchange, in addition to them being lis...

2023-07-05 10:02:39 ET Gainers: Impel Pharmaceuticals ( IMPL ) +32% . Adicet Bio ( ACET ) +18% . C4 Therapeutics ( CCCC ) +17% . NLS Pharmaceutics ( NLSP ) +7% . Poseida Therapeutics ( PSTX ) +4% . Losers: Amneal Pharmaceu...

2023-07-05 08:14:54 ET Amneal Pharmaceuticals ( AMRX ) -13% . Advanced Health Intelligence ( AHI ) -10% . Landos Biopharma ( LABP ) -10% . InterCure ( INCR ) -9% . Alliance Entertainment Holding Corporation ( AENT ) -9% . Renalyt...

NEW YORK and TORONTO and HERZLIYA, Israel, June 09, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd . (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc)(" InterCure " or the " Compan y "), reports today that, further to the Company’s press release issued on February 1, 2023, wh...

2023-05-16 03:24:42 ET InterCure press release ( NASDAQ: INCR ): Q1 GAAP EPS of NIS 0.005. Revenue of NIS 106M (+21.5% Y/Y). Adjusted EBITDA for the first quarter was NIS 16 million. Cash and restricted cash (consolidated) at quarter end of NIS 120 million. F...

NEW YORK, TORONTO, and HERZLIYA, Israel, May 15, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd . (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc)("InterCure") today announced that Alexander Rabinovitch, CEO of InterCure, will participate in the Cowen 3 rd Annual European Cannabis Conferen...

Achieved record revenues of $40 million for the first quarter Annualized revenue run rate of $159 million Adjusted EBITDA (1) of $6 Million Strong balance sheet with over $45 million cash and Net current assets of over $72 million NEW YORK, TORONTO, and HERZLIYA, Israel, May...

NEW YORK and TORONTO and HERZLIYA, Israel, May 15, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: INCR ) (TSX: INCR.U) (TASE: INCR) ("InterCure'' or the "Company"), the largest and fastest growing medical cannabis company outside of North America, is pleased to announce that its Chairman and former Pr...